European Alliance of Associations for Rheumatology (EULAR), 2024

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label, Phase 1b CHERISH Study

Long-Term Sustained Efficacy and Safety of Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

Purified monoclonal rheumatoid factors bind to Fc containing TNF inhibitors in vitro but not to the Fc-free TNF inhibitor, certolizumab pegol

Time to Diagnosis and Associated Comorbidity Burden in Axial Spondyloarthritis in General Practice in France: Results from the THIN® Database

Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and its Open-Label Extension

Impact of Bimekizumab on MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from the BE MOBILE 1 and 2 Phase 3 Studies